Evidence map›Paper›PMID 40371663›Full record

ArticleAging cell2025

hTERT Increases TRF2 to Induce Telomere Compaction and Extend Cell Replicative Lifespan.

Nancy Adam, Yang Yang, Mahbod Djamshidi, Sara Seifan, Nicholas S Y Ting, Joel Glover, Nicolas Touret, Paul M K Gordon, K V Vineetha Warriyar, Hokan Krowicki and 6 more

Abstract read
In one paragraph

Article in Aging cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nancy AdamRobson DNA Science Centre, Arnie Charbonneau Cancer Institute, Departments of Biochemistry & Molecular Biology and/or Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Yang YangRobson DNA Science Centre, Arnie Charbonneau Cancer Institute, Departments of Biochemistry & Molecular Biology and/or Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Mahbod DjamshidiRobson DNA Science Centre, Arnie Charbonneau Cancer Institute, Departments of Biochemistry & Molecular Biology and/or Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Sara SeifanDivision of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
Nicholas S Y TingRobson DNA Science Centre, Arnie Charbonneau Cancer Institute, Departments of Biochemistry & Molecular Biology and/or Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Joel GloverLive Cell Imaging Laboratory, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Nicolas TouretDepartment of Biochemistry, University of Alberta, Edmonton, Alberta, Canada.
Paul M K GordonCentre for Health Genomics and Informatics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
K V Vineetha WarriyarAlberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Hokan KrowickiRobson DNA Science Centre, Arnie Charbonneau Cancer Institute, Departments of Biochemistry & Molecular Biology and/or Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Christine Kim GarciaIrving Medical Center, Columbia University, New York, New York, USA.
Sharon A SavageClinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Aaron A GoodarziRobson DNA Science Centre, Arnie Charbonneau Cancer Institute, Departments of Biochemistry & Molecular Biology and/or Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Duncan M BairdDivision of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
Tara L BeattieRobson DNA Science Centre, Arnie Charbonneau Cancer Institute, Departments of Biochemistry & Molecular Biology and/or Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Karl RiabowolRobson DNA Science Centre, Arnie Charbonneau Cancer Institute, Departments of Biochemistry & Molecular Biology and/or Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0002-5318-2536

Funding

Institute of Aging PJT-190171
6 · The paper itself

Abstract

Replicative senescence occurs in response to shortened telomeres and is triggered by ATM and TP53-mediated DNA damage signaling that blocks replication. hTERT lengthens telomeres, which is thought to block damage signaling and the onset of senescence. We find that normal diploid fibroblasts expressing hTERT mutants unable to maintain telomere length do not initiate DNA damage signaling and continue to replicate, despite having telomeres shorter than senescent cells. The TRF1 and TRF2 DNA binding proteins of the shelterin complex stabilize telomeres, and we find that expression of different mutant hTERT proteins decreases levels of the Siah1 E3 ubiquitin ligase that targets TRF2 to the proteasome, by increasing levels of the CDC20 and FBXO5 E3 ligases that target Siah1. This restores the TRF2:TRF1 ratio to block the activation of ATM and subsequent activation of TP53 that is usually associated with DNA damage-induced senescence signaling. All hTERT variants reduce DNA damage signaling, and this occurs concomitantly with telomeres assuming a more compact, denser conformation than senescent cells as measured by super-resolution microscopy. This indicates that hTERT variants induce TRF2-mediated telomere compaction that is independent of telomere length, and it plays a dominant role in regulating the DNA damage signaling that induces senescence and blocks replication of human fibroblasts. These observations support the idea that very short telomeres often seen in cancer cells may fail to induce senescence due to selective stabilization of components of the shelterin complex, increasing telomere density, rather than maintaining telomere length via the reverse transcriptase activity of hTERT.

Indexed as

Cellular SenescenceTelomeraseTelomereTelomeric Repeat Binding Protein 2Ataxia Telangiectasia Mutated ProteinsDNA DamageFibroblastsHumansSignal TransductionTumor Suppressor Protein p53Ubiquitin-Protein LigasesAtaxia Telangiectasia Mutated ProteinsTelomeraseTelomeric Repeat Binding Protein 2TERF2 protein, humanTERT protein, humanTumor Suppressor Protein p53Ubiquitin-Protein LigaseshTERT noncanonical activitysenescencetelomere clusteringtelomere compactionTRF2 stabilization

Identifiers

PMID40371663
PMCPMC12341801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.